Philippine Smoke-Free Movement Calls for E-Cigarette Regulation Review

Aug.13.2024
Philippine Smoke-Free Movement Calls for E-Cigarette Regulation Review
Philippine Smoke-Free Movement urges lawmakers to review e-cigarette regulations following first related death case, reports Manila Times.

According to a report by the Manila Times on August 13, the Philippine Smoke-Free Movement (PSFM) is calling on lawmakers to review the e-cigarette regulation law following the first reported death related to e-cigarettes.


Rizal Duro, the national coordinator for PSFM, mentioned during a forum on Monday (12th) a recent report from the Ministry of Health. The report stated that a 22-year-old athlete died from lung damage associated with e-cigarette use (Evali).


Du Luo pointed out that the athlete is in good physical health, with no underlying medical conditions, but has been using e-cigarettes daily for the past two years.


The coordinator cited government data and expressed regret over the sharp increase in the number of teenagers addicted to e-cigarettes.


A recent global survey on tobacco use among teenagers revealed that one in eight children aged 13 to 15 are already smoking, with one in seven preferring e-cigarettes.


Ma. Aurora Quilala, Deputy Executive Director of the Philippine Legislators' Committee on Population and Development (PLCPD), stated that the same data also indicates a failure in "our society and the entire country" in fully protecting the rights and well-being of young people, especially in terms of their health.


Quilala and Duro are both calling for an immediate review of Republic Act 11900 and are requesting that the age limit for the sale and use of e-cigarettes be restored to 21 years old.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

PMI Launches Mass Production of ZYN at $600M Aurora Manufacturing Hub
PMI Launches Mass Production of ZYN at $600M Aurora Manufacturing Hub
Philip Morris International (PMI), through its subsidiary Swedish Match, has started large-scale production at a 600,000-square-foot ZYN nicotine pouch facility in Aurora, Colorado. The $600 million investment makes the site one of three ZYN manufacturing plants in the United States and the company’s second U.S. facility after Owensboro, Kentucky.
PMI
Feb.21
BAT CEO Says 2026 Return to Growth Hinges on U.S. Enforcement, Highlights Oral Leadership
BAT CEO Says 2026 Return to Growth Hinges on U.S. Enforcement, Highlights Oral Leadership
British American Tobacco said 2026 will mark a return to its mid-term growth algorithm, but CEO Tadeu Marroco stressed that deliverywill depend heavily on enforcement against illicit vapour products in the United States. Speaking at the FY2025 results call, he positioned Modern Oral as the company’s primary structural growth engine, reframed accelerating cigarette declines through “poly-usage,” and reinforced capital discipline with an expanded share buyback plan.
Feb.12
UK Vape Waste Falls 23% From 2024, but Recycling Group Says Fire Risks Remain High
UK Vape Waste Falls 23% From 2024, but Recycling Group Says Fire Risks Remain High
New research from UK recycling campaign group Material Focus says more than 6.3 million vapes and pods are still thrown away each week in the UK. The figure is down 23% from 8.2 million in 2024, which the group said suggests the June 2025 single-use vape ban has helped reduce waste, but it warned that the current level still represents a major waste of valuable materials and a significant fire risk.
Mar.27 by 2FIRSTS.ai
KT&G Integrates “lil Aible” Dedicated Stick Lineup Under the “AIIM” Brand
KT&G Integrates “lil Aible” Dedicated Stick Lineup Under the “AIIM” Brand
KT&G said it will integrate the Real, Granular and Vapor Stick product lines for its heated tobacco device “lil Aible” under the “AIIM” brand. The company said the brand integration is intended to organize the existing lineup more intuitively and improve consumer accessibility and convenience.
Mar.18 by 2FIRSTS.ai
Imperial Brands Forms Global AI Partnership with Capgemini, Reinforcing Artificial Intelligence as Core Infrastructure in the Nicotine Industry
Imperial Brands Forms Global AI Partnership with Capgemini, Reinforcing Artificial Intelligence as Core Infrastructure in the Nicotine Industry
Industry Insight
Feb.19
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24